# Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects

> **NCT03329573** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 85 (actual)

## Conditions studied

- Anxiety Disorders

## Interventions

- **DRUG:** Paroxetine IR tablets A
- **DRUG:** Paroxetine IR tablets B

## Key facts

- **NCT ID:** NCT03329573
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2018-08-03
- **Final completion:** 2018-08-03
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2020-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03329573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03329573, "Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03329573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*